Publication | Open Access
Reirradiation of head and neck cancer: Long‐term disease control and toxicity
63
Citations
25
References
2017
Year
Neck CancerTreatment ResistanceTreatment VerificationRadiation MedicineOncologyRadiation Therapy PlanningClinical Radiation OncologyNeck OncologyRadiation OncologyHead And Neck OncologyCancer ResearchRadiologyHealth SciencesRadiation TherapyHead And Neck SurgeryComparative PlanningLate Radiation ToxicityUnderwent ReirradiationNeck PathologyHead And Neck CancerHead And Neck Squamous Cell CarcinomaLong‐term Disease ControlMedicineCancer Therapeutics
ABSTRACT Background The purpose of this study was to report long‐term disease control and late radiation toxicity for patients reirradiated for head and neck cancer. Methods We conducted a retrospective analysis of 137 patients reirradiated with a prescribed dose ≥45 Gy between 1986 and 2013 for a recurrent or second primary malignancy. Endpoints were locoregional control, overall survival (OS), and grade ≥4 late complications according to European Organization for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) criteria. Results Five‐year locoregional control rates were 46% for patients reirradiated postoperatively versus 20% for patients who underwent reirradiation as the primary treatment ( p < .05). Sixteen cases of serious (grade ≥4) late toxicity were seen in 11 patients (actuarial 28% at 5 years). In patients reirradiated with intensity‐modulated radiotherapy (IMRT), a borderline improved locoregional control was observed (49% vs 36%; p = .07), whereas late complication rates did not differ. Conclusion Reirradiation should be considered for patients with a recurrent or second primary head and neck cancer, especially postoperatively, if indicated. © 2017 Wiley Periodicals, Inc. Head Neck 39: 1122–1130, 2017
| Year | Citations | |
|---|---|---|
Page 1
Page 1